FDA-IMS Joint Workshop: Defining Patient Populations for Clinical Studies in Multiple Myeloma

February 22, 2024 - The Hyatt Regency Bethesda, Maryland and Virtual

Outcomes for patients with multiple myeloma have improved with approval of several therapies. Despite this MM, remains incurable. Recent results have also highlighted the heterogeneity in outcomes in patients with multiple myeloma. Improved understanding of the clinical and disease specific prognostic factors and the availability of multiple classes of therapies has necessitated discussions on patient populations for evaluation in clinical trials of novel therapies. Additionally, as new therapies are moved into earlier lines, it is important to evaluate the appropriateness of the control arms for clinical trials.

This workshop is intended to discuss disease setting considerations in MM, with a focus on defining patient populations for enrollment onto clinical trials for MM. This meeting will bring together representatives from the physician community, patients, pharmaceutical industry and regulatory scientists.

Goals and Objectives
– Discuss eligibility criteria for MM clinical trials in different disease settings
– Discuss considerations in defining patient populations
– Review common goals and methods for clinical trial conduct

Preliminary Agenda

Special Thanks

5th Immune Effector Cell Therapies in Multiple Myeloma Workshop

March 23 - 24, 2024 - Boston Marriott Long Wharf, Boston, MA

IMS is pleased to announce that the 5th Annual Immune Effector Cell Therapies in Multiple Myeloma Workshop will take place from March 23-24, 2024 in Boston, MA.

Tentative Agenda

Our sponsors:
Titanium
Platinum
Gold
Silver

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – East Coast

March 27, 2024 - Webinar

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!

This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

Tentative Agenda

Our Sponsors

Practical Insights in Novel Immune Therapies in Multiple Myeloma Webinar – West Coast

April 10, 2024 - Webinar

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this 90-minute webinar is for you!

This high-impact, 90-minute educational program seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

Tentative Agenda

Our Sponsors

Educational Workshop, Buenos Aires, Argentina

April 19 - 20, 2024 - Sheraton Buenos Aires & Convention Center, Buenos Aires, Argentina

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

 

Preliminary Agenda

Our sponsors:
Silver

2nd Annual Genomics Meeting

July 12 - 13, 2024 - Hilton Barcelona, Barcelona, Spain

The IMS Genomics Meeting was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. The publication with the results and recommendations from this meeting has been submitted for review. Building upon this success, the Second IMS Genomics Meeting will be a public meeting led by global myeloma KOL.

In addition to which, this day and a half-long meeting will include sessions on:

  • Risk Stratification validation
  • Genomically targeted therapies
  • New technologies
  • Genomic Biomarkers for stratification of clinical studies
  • New clinical trials for patients with HR disease

21st IMS Annual Meeting

September 25 - 28, 2024 - Rio de Janeiro, Brazil

Mark your calendars for the 21st IMS Annual Meeting in Rio de Janeiro, Brazil!

The 21st IMS Annual Meeting will take place in Rio de Janeiro, Brazil from September 25-28, 2024.

More details will be available soon. 

Our sponsors:
Titanium
Platinum

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events